Business
Avacta Completes Launch Diagnostics Sale
Avacta Completes Launch Diagnostics Sale.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \n \nAvacta Announces Completion of the Sale of Launch Diagnostics\n \nLONDON AND PHILADELPHIA - 25 March 2025 - Further to the announcement made on 7 March 2025, Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that all closing conditions to the sale of the entire issued share capital of Launch Diagnostics Holdings Limited and its subsidiaries, its UK-headquartered and largest diagnostics unit, to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U, have been satisfied and completion of the sale took place yesterday.\n \n \n-Ends-\n \nFor further information from Avacta, please contact:\n \n\n\n\n\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\n\n\nhttps://avacta.com/\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden\n \n \n\n\n \nwww.peelhunt.com\n \n\n\n\n\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\n \n\n\nwww.panmureliberum.com\n\n\n\n\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Max Bennett\n\n\n \[email protected]\n \n\n\n\n\n \nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\n \n\n\n \n \[email protected]\n \n\n\n\n\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\n\n\n \[email protected] \n\n\n\n\n \n \nAbout Avacta - https://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\n \nAbout the pre|CISION® Platform\nThe pre|CISION® platform comprises an anticancer payload conjugated to a pr...